An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report

Abstract Background Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is selective for both epidermal growth factor receptor tyrosine kinase inhibitor–sensitizing and T790M resistance mutations. Almost all patients who initially respond to an epidermal growt...

Full description

Bibliographic Details
Main Authors: Shinichi Miyazaki, Yasumasa Kuno, Shunsaku Hayai, Ryo Teramachi, Ryo Yamashita, Yusuke Saito, Kosuke Higuchi, Yoshiharu Nara, Takuya Ikeda
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Journal of Medical Case Reports
Subjects:
Epidermal growth factor receptor
T790M
Osimertinib
Large-cell neuroendocrine carcinoma
Transformation
Online Access:http://link.springer.com/article/10.1186/s13256-020-02447-0

Internet

http://link.springer.com/article/10.1186/s13256-020-02447-0

Similar Items